Bioatla Inc (BCAB)
$2.53
Insights on Bioatla Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 79.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 339.8%
Performance
- $2.52$2.75$2.53
0.59%
Downside
Day's Volatility :8.55%
Upside
8.0%
- $1.24$4.07$2.53
50.99%
Downside
52 Weeks Volatility :69.53%
Upside
37.84%
Returns
| Period | Bioatla Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 21.63% | -0.7% | 0.0% |
6 Months | 42.94% | 6.6% | 0.0% |
1 Year | -33.07% | 3.7% | -1.5% |
3 Years | -94.72% | 14.0% | -21.8% |
Highlights
Market Capitalization | 126.3M |
Book Value | $1.47 |
Earnings Per Share (EPS) | -2.58 |
Wall Street Target Price | 11.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -46.93% |
Return On Equity TTM | -98.37% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 31.6% |
Gross Profit TTM | -79.3M |
EBITDA | -128.5M |
Diluted Eps TTM | -2.58 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.76 |
EPS Estimate Next Year | -1.93 |
EPS Estimate Current Quarter | -0.79 |
EPS Estimate Next Quarter | -0.54 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 354.55%
Technicals Summary
Sell
Neutral
Buy
Bioatla Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Bioatla Inc | 8.12% | 42.94% | -33.07% | -94.72% | -91.84% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Bioatla Inc | NA | NA | NA | -2.76 | -0.98 | -0.47 | NA | 1.47 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Bioatla Inc | Buy | $126.3M | -91.84% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Soleus Capital Management, L.P.
8.48%TANG CAPITAL MANAGEMENT LLC
7.88%BlackRock Inc
6.02%Vanguard Group Inc
4.34%Morgan Stanley - Brokerage Accounts
3.99%Cormorant Asset Management, LLC
2.46%
Corporate Announcements
Bioatla Inc Earnings
Bioatla Inc’s price-to-earnings ratio stands at None
Read More
Company Information
bioatla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. the culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our conditionally active biologics (cab) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. this improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. bioatla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
Organization | Bioatla Inc |
Employees | 65 |
CEO | Dr. Jay M. Short Ph.D. |
Industry | Healthcare |
